A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer

被引：0
|
作者：
Jinno, H. [1 ]
Sato, T. [1 ]
Takahashi, M. [1 ]
Hayashida, T. [1 ]
Sakata, M. [1 ]
Hirose, S. [1 ]
Kitagawa, Y. [1 ]
机构：
[1] Keio Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11070
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] A Phase II Preoperative Trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline in HER2-Positive Operable Breast Cancer
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Sakata, M.
    Jinno, H.
    Hirose, S.
    Mukai, M.
    Kitagawa, Y.
    [J]. CANCER RESEARCH, 2010, 70
  • [3] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [4] Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
    Conte, Benedetta
    Montemurro, Filippo
    Levaggi, Alessia
    Blondeaux, Eva
    Molinelli, Chiara
    Cardinali, Barbara
    Poggio, Francesca
    Buzzatti, Giulia
    Bighin, Claudia
    Lambertini, Matteo
    Del Mastro, Lucia
    [J]. TUMORI JOURNAL, 2023, 109 (01): : 71 - 78
  • [5] Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute
    Yardley, Denise A.
    Zubkus, John D.
    Eakle, Janice F.
    Bechhold, Rebecca G.
    Finney, Lindsey
    Daniel, Davey
    Daniel, Brooke
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2015, 15 (04) : 251 - 258
  • [6] Neoadjuvant trastuzumab therapy with or without anthracycline containing chemotherapy for HER2-positive primary breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Odawara, H.
    Tokiniwa, H.
    Kikuchi, M.
    Lino, Y.
    Takeyoshi, I.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 73 - 73
  • [7] Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
    Levaggi, A.
    Poggio, F.
    Lambertini, M.
    D'Alonzo, A.
    Giraudi, S.
    Bighin, C.
    Blondeaux, E.
    Pastorino, S.
    Abate, A.
    Iacono, G.
    Vaglica, M.
    Conte, B.
    Pronzato, P.
    Del Mastro, L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer
    Ahluwalia, MS
    Daw, HA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7759 - 7760
  • [9] Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer
    Ferretti, Gianluigi
    Felici, Alessandra
    Papaldo, Paola
    Carlini, Paolo
    Fabi, Alessandra
    Cognetti, Francesco
    [J]. ONCOLOGIST, 2006, 11 (05): : 533 - 533
  • [10] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    [J]. CANCER RESEARCH, 2012, 72
12345